Microvascular Outcomes after Metabolic Surgery (MOMS) in patients with type 2 diabetes mellitus and class I obesity: rationale and design for a randomised controlled trial.

INTRODUCTION: There are several randomised controlled trials (RCTs) that have already shown that metabolic/bariatric surgery achieves short-term and long-term glycaemic control while there are no level 1A of evidence data regarding the effects of surgery on the microvascular complications of type 2 diabetes mellitus (T2DM). PURPOSE: The aim of this trial is to investigate the long-term efficacy and safety of the Roux-en-Y gastric bypass (RYGB) plus the best medical treatment (BMT) versus the BMT alone to improve microvascular outcomes in patients with T2DM with a body mass index (BMI) of 30-34.9 kg/m2. METHODS AND ANALYSIS: This study design includes a unicentric randomised unblinded controlled trial. 100 patients (BMI from 30 to 34.9 kg/m2) will be randomly allocated to receive either RYGB plus BMT or BMT alone. The primary outcome is the change in the urine albumin-to-creatinine ratio (uACR) captured as the proportion of patients who achieved nephropathy remission (uACR<30 mg/g of albumin/mg of creatinine) in an isolated urine sample over 12, 24 and 60 months. ETHICS AND DISSEMINATION: The study was approved by the local Institutional Review Board. This study represents the first RCT comparing RYGB plus BMT versus BMT alone for patients with T2DM with a BMI below 35 kg/m2. TRIAL REGISTRATION NUMBER: NCT01821508; Pre-results.

Laparoscopic bariatric surgery: new technologies, trends and perspectives.

Obesity is an endemic disease. It was already proved that the clinical approach to morbid obesity fails in 95% of cases. Laparoscopy has shown that is related to a milder metabolic response and a smoother postoperative period. There is no doubt that the laparoscopic approach is not the future for the surgical treatment of morbid obesity, but the best present approach and with equally excellent results when compared to the traditional open operation. However, this challenging surgery requires masterful use of an array of specialized laparoscopic equipment and instrumentation. These include proper video monitors, cameras, visualization, peritoneal entrance, scopes, cutting/coagulation equipments, and staplers, suturing devices, graspers, dedicated endosurgery operating rooms, robotics and awareness of newer equipment. This paper covers the benefits of the laparoscopic access in bariatric surgery and reviews the cutting-edge in technology to drive surgeons and patients to a smoother intra and postoperative course.

Laparoscopic bariatric surgery: new technologies, trends and perspectives

Obesidade hoje é uma doença endêmica. Está comprovado que o tratamento clínico falha em 95% dos casos. A Cirurgia Laparoscópica já demonstrou ser menos agressiva do ponto de vista sistêmico e metabólico, levando a um pós-operatório mais confortável. Hoje, não existe dúvida que o acesso laparoscópico não é o futuro, mas sim o presente para o tratamento operatório da obesidade mórbida, tendo, pelo menos, os excelentes resultados em termos de perda ponderal e cura das co morbidades quando comparada às operações abertas. Porém, essas operações, por vezes, necessitam de um grande aparato tecnológico, como videocâmeras, monitores de alta resolução, laparoscópios, equipamentos para corte e coagulação eficientes e seguros e até mesmo salas cirúrgicas devotadas às operações minimamente invasivas. Esse artigo discorre sobre os benefícios do acesso laparoscópico, assim como revisa a tecnologia de ponta que pode ser utilizada pela equipe cirúrgica para a condução segura, rápida e eficiente das operações bariátricas por videolaparoscopia.